SVB Leerink Downgrades Design Therapeutics to Market Perform, Announces $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
SVB Leerink analyst Joseph Schwartz has downgraded Design Therapeutics (NASDAQ:DSGN) from Outperform to Market Perform and set a price target of $6.
August 15, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Design Therapeutics has been downgraded by SVB Leerink from Outperform to Market Perform with a price target of $6.
The downgrade from Outperform to Market Perform by SVB Leerink indicates a less optimistic outlook for Design Therapeutics. This could potentially lead to a decrease in the stock's price in the short term. The price target of $6 also suggests a potential downside from the current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100